
    
      Multicentre study with 4 parallel groups. One group will receive GSK134612 co-administered
      with Infanrix hexa™, two groups will receive sequential administration of GSK134612 and
      Infanrix hexa™ and the final group will receive Meningitec™.

      For subjects in Groups B and C, three blood samples will be taken: prior to first vaccination
      and 1 month after each vaccination.

      For subjects in Groups A and D, two blood samples will be taken: prior to and 1 month after
      vaccination.
    
  